Home News Page 3

News

U.S. Food and Drug Administration Rejects Sacituzumab Govitecan

The U.S. Food and Drug Administration (FDA) has rejected sacituzumab govitecan also known as IMMU-132, a novel, investigational, antibody-drug...
MabPlex

MabPlex’s Manufactured Monoclonal Antibody Receives IND Approval from the U.S. Food and Drug Administration

Leading Contract Development and Manufacturing Organization (CDMO) MabPlex International, serving the global biopharmaceutical and biotechnology industries with sites in...

First Patient Dosed in Phase I Trial with Pyrrolobenzodiazepine-based Antibody-drug conjugate Targeting AXL in...

The development of proprietary, pyrrolobenzodiazepine-based, antibody-drug conjugates or ADCs targeting AXL, has entered a news phase with the dosing...

Study Demonstrates that Targeting EphA3 Expressing Tumor Stem Cells and Neovasculature is a Viable...

The Eph type-A receptor 3 (also known as EphA3 receptor) is recognized as a functional tumor-specific therapeutic target in...

CytomX Therapeutics Acquires Technologies Developed by Agensys

Clinical-stage and oncology-focused biopharmaceutical company CytomX Therapeutics, pioneering a novel class of investigational antibody therapeutics based on its Probody™...

First Patient Dosed in Phase Ib Clinical Trial of Camidanlumab Tesirine in Patients with...

A first patient has been dosed in Phase Ib clinical trial of camidanlumab tesirine, also know ADCT-301, a proprietary...

Mersana Therapeutics Licenses GlycoConnect™ Site-Specific ADC Technology from Synaffix

Mersana Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers...

Mersana Therapeutics Focuses its Resources on Advancing XMT-1536, its First-in-Class ADC Candidate Targeting NaPi2b

Mersana Therapeutics, a clinical-stage biopharmaceutical company developing a pipeline of antibody-drug conjugates or ADCs designed to target cancers in...

Novel Payloads for Antibody-drug Conjugates

The development of antibody-drug conjugates or ADCs, has resulted in the need of developing novel compounds that can be...

Novel Method to Quickly Develop Site Specific ADCs

Scientists at William Marsh Rice University, commonly known as Rice University, a private research university located in Houston, Texas,...